NASDAQ:DEPO - Depomed Stock Price, Price Target & More

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

Depomed Inc (NASDAQ:DEPO) announced its quarterly earnings data on Thursday, May, 10th. The specialty pharmaceutical company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.69. The specialty pharmaceutical company earned $128.40 million during the quarter, compared to the consensus estimate of $65.77 million. Depomed had a negative net margin of 10.02% and a negative return on equity of 15.74%. The company's quarterly revenue was up 41.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.07 EPS. View Depomed's Earnings History.

Depomed is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Depomed.

7 equities research analysts have issued 1 year price targets for Depomed's shares. Their predictions range from $5.00 to $10.00. On average, they expect Depomed's share price to reach $8.2857 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price. View Analyst Ratings for Depomed.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Depomed include Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH), Phibro Animal Health (PAHC), Insmed (INSM), Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO) and Innoviva (INVA).

Media headlines about DEPO stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Depomed earned a news impact score of 0.11 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 45.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Depomed's stock is owned by many different of institutional and retail investors. Top institutional investors include STARBOARD VALUE LP (6.10%), STARBOARD VALUE LP (4.30%) and Campbell & CO Investment Adviser LLC (0.07%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

DEPO stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Depomed.

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DEPO stock can currently be purchased for approximately $8.21.

Depomed has a market capitalization of $522.05 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]